

Supplementary table 1

The questionnaire	
1.	<p>In which health-care region of Denmark are you employed?</p> <ul style="list-style-type: none"> Response options: (1) North Denmark Region, (2) Central Denmark Region, (3) Region of Southern Denmark, (4) Region Zealand, (5) Capital Region of Denmark or (6) other (please specify).
2.	<p>What is your position at the hospital?</p> <ul style="list-style-type: none"> Response options: (1) Senior consultant*, (2) Consultant**, (3) Specialty registrar***, (4) Junior registrar**** or (5) other (please specify).
3.	<p>How many years of experience do you have in nAMD diagnostics?</p> <ul style="list-style-type: none"> Response options: (1) No experience, (2) less than 1 year, (3) 1-2 years, (4) 2-5 years or (5) more than 5 years.
4.	<p>Which modalities do you primarily use in the diagnosis of nAMD? (Select one or more)</p> <ul style="list-style-type: none"> Response options: (1) Fundoscopy, (2) fundus photography, (3) OCT, (4) Fluorescein angiography (FA), (5) Indocyanine green angiography (ICGA), (6) OCT angiography (OCT-A) or (7) other (please specify).
5.	<p>Is OCT-A available at your department for clinical use?</p> <ul style="list-style-type: none"> Response options: (1) Yes, (2) no or comments.
6.	<p>If "Yes" to question 5: Which types of OCT-A devices are available at your department? (Please specify all available types)</p> <ul style="list-style-type: none"> Response options: (1) ZEISS Angioplex, (2) Optovue AngioVue, (3) Topcon, (4) Heidelberg or (5) other types (please specify).
7.	<p>How many years of experience do you have with the use and interpretation of OCT-A?</p> <ul style="list-style-type: none"> Response options: (1) No experience, (2) less than 1 year, (3) 1-2 years, (4) 2-5 years or (5) more than 5 years.
8.	<p>Do you consider your training in operating OCT-A devices and interpretation of OCT-A sufficient?</p> <ul style="list-style-type: none"> Response options: (1) Yes, (2) no, (3) I haven't had training or comments:
9.	<p>Does your department have guidelines on the use of OCT-A for making decisions on anti-VEGF treatment in nAMD patients?</p> <ul style="list-style-type: none"> Response options: (1) Yes, (2) No, (3) I don't know or comments.
10.	<p>How many years of experience do you have with making decisions on anti-VEGF treatment in nAMD patients?</p> <ul style="list-style-type: none"> Response options: (1) No experience, (2) less than 1 year, (3) 1-2 years, (4) 2-5 years or (5) more than 5 years.
11.	<p>How often do you use OCT-A to guide decisions on anti-VEGF treatment in nAMD patients?</p> <ul style="list-style-type: none"> Response options: (1) Never, (2) rarely, (3) sometimes, (4) often or (5) always.
12.	<p>If the answer to question 10 wasn't "No experience": How often do you use OCT-A without simultaneous invasive contrast-based angiography to guide decisions on anti-VEGF treatment in nAMD patients?</p>

	<ul style="list-style-type: none"> Response options: Never, rarely, sometimes, often or always.
13.	<p>If the answer to question 10 wasn't "No experience": Have you made the decision to initiate anti-VEGF treatment in more than ten nAMD patients?</p> <ul style="list-style-type: none"> Response options: (1) Yes, (2) no or (3) don't know.
14.	<p>If "Yes" to question 13: Of the last 10 patients with suspected nAMD that you considered for initiation of anti-VEGF treatment, please specify how many times you used the following combinations of diagnostic methods:</p> <ul style="list-style-type: none"> Response options: (1) Clinical signs of activity alone (e.g. haemorrhage or intraretinal oedema on OCT), (2) OCT-A in combination with clinical signs of activity (e.g. haemorrhage or intraretinal oedema on OCT), (3) OCT-A alone, (4) FA/ICGA in combination with clinical signs of activity (e.g. haemorrhage or intraretinal oedema on OCT), (5) FA/ICGA alone, (6) FA/ICGA in combination with OCT-A or (7) Others (Please specify the modalities).
15.	<p>If the answer to question 10 was not "No experience": Why do you use OCT-A and/or FA/ICGA to guide decisions on anti-VEGF treatment in nAMD patients?</p> <ul style="list-style-type: none"> Response options: Comments.
16.	<p>What limitations do you experience with OCT-A in nAMD patients?</p> <ul style="list-style-type: none"> Response options: Comments.
17.	<p>What limitations do you experience with invasive contrast-based angiography in nAMD patients?</p> <ul style="list-style-type: none"> Response options: Comments:
18.	<p>Please elaborate on other factors that are considered in your use of OCT-A in patients with nAMD?</p> <ul style="list-style-type: none"> Response options: Comments
<p>* Senior consultant: Senior physician working as a specialist in ophthalmology ** Consultant: Physician working as a specialist in ophthalmology *** Specialty registrar: Physician in their second to final year of specialty training in ophthalmology. **** Junior registrar: Physician in their first year of specialty training in ophthalmology'</p>	

Supplementary table 2

Characteristics of survey respondents.

ID	Health-care region of employment	Position	Experience with nAMD diagnostics	Experience with initiation of anti-VEGF treatment	Experience with use and interpretation of OCT-A
1	Capital Region of Denmark	Senior consultant *	> 5 years	> 5 years	2-5 years

2	Region of Southern Denmark	Senior consultant *	> 5 years	> 5 years	2-5 years
3	Region of Southern Denmark	Consultant **	2-5 years	2-5 years	2-5 years
4	Region of Southern Denmark	Consultant **	2-5 years	> 5 years	2-5 years
5	<i>Capital Region of Denmark</i>	Junior registrar ****	1-2 years	1-2 years	1-2 years
6	Region of Southern Denmark	Consultant **	2-5 years	2-5 years	2-5 years
7	Central Region Denmark	Senior consultant *	> 5 years	> 5 years	2-5 years
8	<i>Capital Region of Denmark</i>	Senior consultant *	> 5 years	> 5 years	2-5 years
9	North Denmark Region	Consultant **	2-5 years	2-5 years	2-5 years
10	Region of Southern Denmark	Senior consultant *	> 5 years	> 5 years	2-5 years
11	Central Region Denmark	Senior consultant *	> 5 years	> 5 years	2-5 years
12	North Denmark Region	Specialty registrar***	< 1 year	< 1 year	< 1 year
13	Central Region Denmark	Consultant **	> 5 years	> 5 years	2-5 years
14	Region Zealand	Specialty registrar***	< 1 year	< 1 year	< 1 year
15	Region Zealand	Consultant **	> 5 years	> 5 years	1-2 years
16	<i>Capital Region of Denmark</i>	Specialty registrar***	2-5 years	2-5 years	1-2 years
17	Region Zealand	Specialty registrar***	> 5 years	> 5 years	< 1 year

18	Region of Southern Denmark	Consultant **	> 5 years	> 5 years	2-5 years
19	Region Zealand	Senior consultant *	> 5 years	> 5 years	1-2 years
20	<i>Capital Region of Denmark</i>	Senior consultant *	> 5 years	> 5 years	> 5 years
21	North Denmark Region	Consultant **	> 5 years	> 5 years	2-5 years